{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:07:13Z","timestamp":1794002833493,"version":"4.8.0"},"reference-count":189,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Genet"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1038\/s41576-019-0205-4","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T06:02:57Z","timestamp":1581314577000},"page":"255-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1181,"title":["Engineering adeno-associated virus vectors for gene therapy"],"prefix":"10.1038","volume":"21","author":[{"given":"Chengwen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Jude","family":"Samulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"key":"205_CR1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1080\/14712598.2017.1356817","volume":"17","author":"NA Moore","year":"2017","unstructured":"Moore, N. A., Bracha, P., Hussain, R. M., Morral, N. & Ciulla, T. A. Gene therapy for age-related macular degeneration. Expert. Opin. Biol. Ther. 17, 1235\u20131244 (2017).","journal-title":"Expert. Opin. Biol. Ther."},{"key":"205_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.immuni.2019.02.005","volume":"50","author":"JM Martinez-Navio","year":"2019","unstructured":"Martinez-Navio, J. M. et al. Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression. Immunity 50, 567\u2013575.e5 (2019).","journal-title":"Immunity"},{"key":"205_CR3","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.hlc.2018.03.005","volume":"27","author":"S Bass-Stringer","year":"2018","unstructured":"Bass-Stringer, S. et al. Adeno-associated virus gene therapy: translational progress and future prospects in the treatment of heart failure. Heart Lung Circ. 27, 1285\u20131300 (2018).","journal-title":"Heart Lung Circ."},{"key":"205_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4672","volume":"359","author":"CE Dunbar","year":"2018","unstructured":"Dunbar, C. E. et al. Gene therapy comes of age. Science 359, eaan4672 (2018).","journal-title":"Science"},{"key":"205_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1146\/annurev-bioeng-071813-104938","volume":"17","author":"MA Kotterman","year":"2015","unstructured":"Kotterman, M. A., Chalberg, T. W. & Schaffer, D. V. Viral vectors for gene therapy: translational and clinical outlook. Annu. Rev. Biomed. Eng. 17, 63\u201389 (2015).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"205_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/diseases6020042","volume":"6","author":"K Lundstrom","year":"2018","unstructured":"Lundstrom, K. Viral vectors in gene therapy. Diseases 6, 42 (2018).","journal-title":"Diseases"},{"key":"205_CR7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nrg2971","volume":"12","author":"MA Kay","year":"2011","unstructured":"Kay, M. A. State-of-the-art gene-based therapies: the road ahead. Nat. Rev. Genet. 12, 316\u2013328 (2011).","journal-title":"Nat. Rev. Genet."},{"key":"205_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/emmm.201202291","volume":"5","author":"H Buning","year":"2013","unstructured":"Buning, H. Gene therapy enters the pharma market: the short story of a long journey. EMBO Mol. Med. 5, 1\u20133 (2013).","journal-title":"EMBO Mol. Med."},{"key":"205_CR9","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1038\/mt.2012.194","volume":"20","author":"S Yla-Herttuala","year":"2012","unstructured":"Yla-Herttuala, S. Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol. Ther. 20, 1831\u20131832 (2012).","journal-title":"Mol. Ther."},{"key":"205_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.15252\/emmm.201707573","volume":"9","author":"A Aiuti","year":"2017","unstructured":"Aiuti, A., Roncarolo, M. G. & Naldini, L. Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Mol. Med. 9, 737\u2013740 (2017).","journal-title":"EMBO Mol. Med."},{"key":"205_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"205_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1146\/annurev-virology-092818-015530","volume":"6","author":"AM Keeler","year":"2019","unstructured":"Keeler, A. M. & Flotte, T. R. Recombinant adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): where are we, and how did we get here? Annu. Rev. Virol. 6, 601\u2013621 (2019).","journal-title":"Annu. Rev. Virol."},{"key":"205_CR13","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","volume":"14","author":"Z Wu","year":"2006","unstructured":"Wu, Z., Asokan, A. & Samulski, R. J. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 14, 316\u2013327 (2006).","journal-title":"Mol. Ther."},{"key":"205_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/hum.2015.025","volume":"26","author":"E Hastie","year":"2015","unstructured":"Hastie, E. & Samulski, R. J. Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success \u2014 a personal perspective. Hum. Gene Ther. 26, 257\u2013265 (2015).","journal-title":"Hum. Gene Ther."},{"key":"205_CR15","doi-asserted-by":"publisher","first-page":"10405","DOI":"10.1073\/pnas.162250899","volume":"99","author":"Q Xie","year":"2002","unstructured":"Xie, Q. et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl Acad. Sci. USA 99, 10405\u201310410 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"205_CR16","doi-asserted-by":"publisher","first-page":"11556","DOI":"10.1128\/JVI.01536-06","volume":"80","author":"L Govindasamy","year":"2006","unstructured":"Govindasamy, L. et al. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J. Virol. 80, 11556\u201311570 (2006).","journal-title":"J. Virol."},{"key":"205_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.coph.2015.08.002","volume":"24","author":"H Buning","year":"2015","unstructured":"Buning, H., Huber, A., Zhang, L., Meumann, N. & Hacker, U. Engineering the AAV capsid to optimize vector\u2013host-interactions. Curr. Opin. Pharmacol. 24, 94\u2013104 (2015).","journal-title":"Curr. Opin. Pharmacol."},{"key":"205_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrg3742","volume":"15","author":"MA Kotterman","year":"2014","unstructured":"Kotterman, M. A. & Schaffer, D. V. Engineering adeno-associated viruses for clinical gene therapy. Nat. Rev. Genet. 15, 445\u2013451 (2014). This review describes, in detail, the development of AAV mutants using directed evolution.","journal-title":"Nat. Rev. Genet."},{"key":"205_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.coviro.2017.06.003","volume":"24","author":"S Pillay","year":"2017","unstructured":"Pillay, S. & Carette, J. E. Host determinants of adeno-associated viral vector entry. Curr. Opin. Virol. 24, 124\u2013131 (2017).","journal-title":"Curr. Opin. Virol."},{"key":"205_CR20","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1128\/JVI.79.4.2528-2540.2005","volume":"79","author":"S Bleker","year":"2005","unstructured":"Bleker, S., Sonntag, F. & Kleinschmidt, J. A. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J. Virol. 79, 2528\u20132540 (2005).","journal-title":"J. Virol."},{"key":"205_CR21","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1128\/JVI.79.9.5296-5303.2005","volume":"79","author":"S Kronenberg","year":"2005","unstructured":"Kronenberg, S., Bottcher, B., von der Lieth, C. W., Bleker, S. & Kleinschmidt, J. A. A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J. Virol. 79, 5296\u20135303 (2005).","journal-title":"J. Virol."},{"key":"205_CR22","doi-asserted-by":"publisher","first-page":"8732","DOI":"10.1128\/JVI.74.18.8732-8739.2000","volume":"74","author":"RP Haberman","year":"2000","unstructured":"Haberman, R. P., McCown, T. J. & Samulski, R. J. Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A\/D junction element. J. Virol. 74, 8732\u20138739 (2000).","journal-title":"J. Virol."},{"key":"205_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/sj.mt.6300355","volume":"16","author":"Z Wu","year":"2008","unstructured":"Wu, Z. et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol. Ther. 16, 280\u2013289 (2008).","journal-title":"Mol. Ther."},{"key":"205_CR24","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","volume":"363","author":"JR Mendell","year":"2010","unstructured":"Mendell, J. R. et al. Dystrophin immunity in Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 363, 1429\u20131437 (2010).","journal-title":"N. Engl. J. Med."},{"key":"205_CR25","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"LA George","year":"2017","unstructured":"George, L. A. et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N. Engl. J. Med. 377, 2215\u20132227 (2017).","journal-title":"N. Engl. J. Med."},{"key":"205_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11095-018-2554-7","volume":"36","author":"GA Rodrigues","year":"2018","unstructured":"Rodrigues, G. A. et al. Pharmaceutical development of AAV-based gene therapy products for the eye. Pharm. Res. 36, 29 (2018).","journal-title":"Pharm. Res."},{"key":"205_CR27","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani, A. C. et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371, 1994\u20132004 (2014).","journal-title":"N. Engl. J. Med."},{"key":"205_CR28","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","volume":"365","author":"AC Nathwani","year":"2011","unstructured":"Nathwani, A. C. et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357\u20132365 (2011).","journal-title":"N. Engl. J. Med."},{"key":"205_CR29","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno, C. S. et al. Successful transduction of liver in hemophilia by AAV\u2013factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342\u2013347 (2006). This paper is the first report of successful gene therapy using an AAV vector in patients with haemophilia; the paper also shows that transduced target cells are eliminated by capsid-specific CTLs.","journal-title":"Nat. Med."},{"key":"205_CR30","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan, S. et al. AAV5\u2013factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519\u20132530 (2017).","journal-title":"N. Engl. J. Med."},{"key":"205_CR31","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","volume":"107","author":"AC Nathwani","year":"2006","unstructured":"Nathwani, A. C. et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 107, 2653\u20132661 (2006).","journal-title":"Blood"},{"key":"205_CR32","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1089\/hum.2013.065","volume":"24","author":"Y He","year":"2013","unstructured":"He, Y. et al. Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical. Hum. Gene Ther. 24, 545\u2013553 (2013).","journal-title":"Hum. Gene Ther."},{"key":"205_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120474","volume":"3","author":"W Shao","year":"2018","unstructured":"Shao, W. et al. Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction. JCI Insight 3, e120474 (2018). This study demonstrates activation of the innate immune response in the later phase of AAV transduction in human cells.","journal-title":"JCI Insight"},{"key":"205_CR34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrd.2018.158","volume":"17","author":"BE Deverman","year":"2018","unstructured":"Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M. & Sah, D. W. Y. Gene therapy for neurological disorders: progress and prospects. Nat. Rev. Drug. Discov. 17, 767 (2018).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"205_CR35","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/sj.gt.3302134","volume":"10","author":"DM McCarty","year":"2003","unstructured":"McCarty, D. M. et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 10, 2112\u20132118 (2003). This paper describes the development of a novel approach involving the mutation of AAV ITRs to generate self-complementary AAV vectors to achieve faster and higher transgene expression.","journal-title":"Gene Ther."},{"key":"205_CR36","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.ymthe.2003.08.021","volume":"8","author":"H Fu","year":"2003","unstructured":"Fu, H. et al. Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol. Ther. 8, 911\u2013917 (2003).","journal-title":"Mol. Ther."},{"key":"205_CR37","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713\u20131722 (2017). This paper presents findings that led to the second AAV-based drug, Zolgensma, being approved by the FDA.","journal-title":"N. Engl. J. Med."},{"key":"205_CR38","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1089\/hum.2016.128","volume":"28","author":"JA Greig","year":"2017","unstructured":"Greig, J. A. et al. Characterization of adeno-associated viral vector-mediated human factor VIII gene therapy in hemophilia A mice. Hum. Gene Ther. 28, 392\u2013402 (2017).","journal-title":"Hum. Gene Ther."},{"key":"205_CR39","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1089\/hum.2015.001","volume":"26","author":"Z Yan","year":"2015","unstructured":"Yan, Z. et al. Optimization of recombinant adeno-associated virus-mediated expression for large transgenes, using a synthetic promoter and tandem array enhancers. Hum. Gene Ther. 26, 334\u2013346 (2015).","journal-title":"Hum. Gene Ther."},{"key":"205_CR40","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/mt.2014.114","volume":"22","author":"MK Chuah","year":"2014","unstructured":"Chuah, M. K. et al. Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates. Mol. Ther. 22, 1605\u20131613 (2014).","journal-title":"Mol. Ther."},{"key":"205_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/mt.2014.178","volume":"23","author":"MY Rincon","year":"2015","unstructured":"Rincon, M. Y. et al. Genome-wide computational analysis reveals cardiomyocyte-specific transcriptional cis-regulatory motifs that enable efficient cardiac gene therapy. Mol. Ther. 23, 43\u201352 (2015).","journal-title":"Mol. Ther."},{"key":"205_CR42","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/260805a0","volume":"260","author":"J Garel","year":"1976","unstructured":"Garel, J. Quantitative adaptation of isoacceptor tRNAs to mRNA codons of alanine, glycine and serine. Nature 260, 805\u2013806 (1976).","journal-title":"Nature"},{"key":"205_CR43","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1006\/jmbi.1996.0428","volume":"260","author":"H Dong","year":"1996","unstructured":"Dong, H., Nilsson, L. & Kurland, C. G. Co-variation of tRNA abundance and codon usage in Escherichia coli at different growth rates. J. Mol. Biol. 260, 649\u2013663 (1996).","journal-title":"J. Mol. Biol."},{"key":"205_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.0020221","volume":"2","author":"KA Dittmar","year":"2006","unstructured":"Dittmar, K. A., Goodenbour, J. M. & Pan, T. Tissue-specific differences in human transfer RNA expression. PLOS Genet. 2, e221 (2006).","journal-title":"PLOS Genet."},{"key":"205_CR45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.omtm.2018.01.004","volume":"9","author":"HC Brown","year":"2018","unstructured":"Brown, H. C. et al. Target-cell-directed bioengineering approaches for gene therapy of hemophilia A. Mol. Ther. Methods Clin. Dev. 9, 57\u201369 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"205_CR46","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/mt.2011.237","volume":"20","author":"DE Bowles","year":"2012","unstructured":"Bowles, D. E. et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20, 443\u2013455 (2012).","journal-title":"Mol. Ther."},{"key":"205_CR47","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1006\/mthe.2001.0456","volume":"4","author":"D Duan","year":"2001","unstructured":"Duan, D., Yue, Y. & Engelhardt, J. F. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol. Ther. 4, 383\u2013391 (2001).","journal-title":"Mol. Ther."},{"key":"205_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-1-4939-3271-9_2","volume":"1382","author":"ML Hirsch","year":"2016","unstructured":"Hirsch, M. L., Wolf, S. J. & Samulski, R. J. Delivering transgenic DNA exceeding the carrying capacity of AAV vectors. Methods Mol. Biol. 1382, 21\u201339 (2016).","journal-title":"Methods Mol. Biol."},{"key":"205_CR49","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1089\/hum.2013.164","volume":"25","author":"T Koo","year":"2014","unstructured":"Koo, T., Popplewell, L., Athanasopoulos, T. & Dickson, G. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice. Hum. Gene Ther. 25, 98\u2013108 (2014).","journal-title":"Hum. Gene Ther."},{"key":"205_CR50","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1038\/mt.2013.184","volume":"21","author":"ML Hirsch","year":"2013","unstructured":"Hirsch, M. L. et al. Oversized AAV transductifon is mediated via a DNA-PKcs-independent, Rad51C-dependent repair pathway. Mol. Ther. 21, 2205\u20132216 (2013).","journal-title":"Mol. Ther."},{"key":"205_CR51","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/sj.mt.6300322","volume":"16","author":"A Ghosh","year":"2008","unstructured":"Ghosh, A., Yue, Y., Lai, Y. & Duan, D. A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol. Ther. 16, 124\u2013130 (2008).","journal-title":"Mol. Ther."},{"key":"205_CR52","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.omtm.2019.01.003","volume":"12","author":"J Fakhiri","year":"2019","unstructured":"Fakhiri, J. et al. Novel chimeric gene therapy vectors based on adeno-associated virus and four different mammalian bocaviruses. Mol. Ther. Methods Clin. Dev. 12, 202\u2013222 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"205_CR53","doi-asserted-by":"publisher","first-page":"8078","DOI":"10.1073\/pnas.86.20.8078","volume":"86","author":"CH Srivastava","year":"1989","unstructured":"Srivastava, C. H., Samulski, R. J., Lu, L., Larsen, S. H. & Srivastava, A. Construction of a recombinant human parvovirus B19: adeno-associated virus 2 (AAV) DNA inverted terminal repeats are functional in an AAV\u2013B19 hybrid virus. Proc. Natl Acad. Sci. USA 86, 8078\u20138082 (1989).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"205_CR54","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-018-0209-1","volume":"24","author":"L Villiger","year":"2018","unstructured":"Villiger, L. et al. Treatment of a metabolic liver disease by in vivo genome base editing in adult mice. Nat. Med. 24, 1519\u20131525 (2018).","journal-title":"Nat. Med."},{"key":"205_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav4523","volume":"11","author":"P Tornabene","year":"2019","unstructured":"Tornabene, P. et al. Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina. Sci. Transl Med. 11, eaav4523 (2019).","journal-title":"Sci. Transl Med."},{"key":"205_CR56","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1016\/j.jmb.2018.05.022","volume":"430","author":"AK Herrmann","year":"2018","unstructured":"Herrmann, A. K. & Grimm, D. High-throughput dissection of AAV\u2013host interactions: the fast and the curious. J. Mol. Biol. 430, 2626\u20132640 (2018).","journal-title":"J. Mol. Biol."},{"key":"205_CR57","doi-asserted-by":"publisher","first-page":"28814","DOI":"10.1074\/jbc.M113.482380","volume":"288","author":"S Shen","year":"2013","unstructured":"Shen, S. et al. Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. J. Biol. Chem. 288, 28814\u201328823 (2013).","journal-title":"J. Biol. Chem."},{"key":"205_CR58","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.omtm.2018.03.004","volume":"9","author":"D Wang","year":"2018","unstructured":"Wang, D. et al. A rationally engineered capsid variant of AAV9 for systemic CNS-directed and peripheral tissue-detargeted gene delivery in neonates. Mol. Ther. Methods Clin. Dev. 9, 234\u2013246 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"205_CR59","doi-asserted-by":"publisher","first-page":"7827","DOI":"10.1073\/pnas.0802866105","volume":"105","author":"L Zhong","year":"2008","unstructured":"Zhong, L. et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl Acad. Sci. USA 105, 7827\u20137832 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"205_CR60","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/mt.2008.269","volume":"17","author":"H Petrs-Silva","year":"2009","unstructured":"Petrs-Silva, H. et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol. Ther. 17, 463\u2013471 (2009).","journal-title":"Mol. Ther."},{"key":"205_CR61","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1038\/mt.2010.172","volume":"18","author":"DM Markusic","year":"2010","unstructured":"Markusic, D. M. et al. High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048\u20132056 (2010).","journal-title":"Mol. Ther."},{"key":"205_CR62","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1089\/hgtb.2016.054","volume":"27","author":"C Ling","year":"2016","unstructured":"Ling, C., Li, B., Ma, W. & Srivastava, A. Development of optimized AAV serotype vectors for high-efficiency transduction at further reduced doses. Hum. Gene Ther. Methods 27, 143\u2013149 (2016).","journal-title":"Hum. Gene Ther. Methods"},{"key":"205_CR63","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1161\/01.CIR.0000109697.68832.5D","volume":"109","author":"SJ White","year":"2004","unstructured":"White, S. J. et al. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 109, 513\u2013519 (2004).","journal-title":"Circulation"},{"key":"205_CR64","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1006\/mthe.2001.0345","volume":"3","author":"M Grifman","year":"2001","unstructured":"Grifman, M. et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol. Ther. 3, 964\u2013975 (2001).","journal-title":"Mol. Ther."},{"key":"205_CR65","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1142\/S1568558610000197","volume":"5","author":"K Adachi","year":"2010","unstructured":"Adachi, K. & Nakai, H. A new recombinant adeno-associated virus (AAV)-based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31\u201355 (2010).","journal-title":"Gene Ther. Regul."},{"key":"205_CR66","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/nbt856","volume":"21","author":"OJ Muller","year":"2003","unstructured":"Muller, O. J. et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat. Biotechnol. 21, 1040\u20131046 (2003).","journal-title":"Nat. Biotechnol."},{"key":"205_CR67","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/mt.2016.62","volume":"24","author":"J Korbelin","year":"2016","unstructured":"Korbelin, J. et al. Pulmonary targeting of adeno-associated viral vectors by next-generation sequencing-guided screening of random capsid displayed peptide libraries. Mol. Ther. 24, 1050\u20131061 (2016).","journal-title":"Mol. Ther."},{"key":"205_CR68","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/gt.2011.143","volume":"19","author":"K Varadi","year":"2012","unstructured":"Varadi, K. et al. Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800\u2013809 (2012).","journal-title":"Gene Ther."},{"key":"205_CR69","doi-asserted-by":"publisher","first-page":"609","DOI":"10.15252\/emmm.201506078","volume":"8","author":"J Korbelin","year":"2016","unstructured":"Korbelin, J. et al. A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases. EMBO Mol. Med. 8, 609\u2013625 (2016).","journal-title":"EMBO Mol. Med."},{"key":"205_CR70","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nbt1182","volume":"24","author":"N Maheshri","year":"2006","unstructured":"Maheshri, N., Koerber, J. T., Kaspar, B. K. & Schaffer, D. V. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24, 198\u2013204 (2006). This study is the first to apply directed evolution to the selection of AAV vectors with the ability to enhance transgene expression and evade NAbs.","journal-title":"Nat. Biotechnol."},{"key":"205_CR71","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/mt.2011.22","volume":"19","author":"N Pulicherla","year":"2011","unstructured":"Pulicherla, N. et al. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol. Ther. 19, 1070\u20131078 (2011).","journal-title":"Mol. Ther."},{"key":"205_CR72","first-page":"553","volume":"9","author":"CA Voigt","year":"2002","unstructured":"Voigt, C. A., Martinez, C., Wang, Z. G., Mayo, S. L. & Arnold, F. H. Protein building blocks preserved by recombination. Nat. Struct. Biol. 9, 553\u2013558 (2002).","journal-title":"Nat. Struct. Biol."},{"key":"205_CR73","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ymthe.2017.09.006","volume":"26","author":"DS Ojala","year":"2018","unstructured":"Ojala, D. S. et al. In vivo selection of a computationally designed SCHEMA AAV library yields a novel variant for infection of adult neural stem cells in the SVZ. Mol. Ther. 26, 304\u2013319 (2018).","journal-title":"Mol. Ther."},{"key":"205_CR74","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/mt.2014.139","volume":"22","author":"D Marsic","year":"2014","unstructured":"Marsic, D. et al. Vector design tour de force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants. Mol. Ther. 22, 1900\u20131909 (2014).","journal-title":"Mol. Ther."},{"key":"205_CR75","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","volume":"34","author":"BE Deverman","year":"2016","unstructured":"Deverman, B. E. et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204\u2013209 (2016).","journal-title":"Nat. Biotechnol."},{"key":"205_CR76","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","volume":"20","author":"KY Chan","year":"2017","unstructured":"Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20, 1172\u20131179 (2017).","journal-title":"Nat. Neurosci."},{"key":"205_CR77","doi-asserted-by":"publisher","first-page":"189ra176","DOI":"10.1126\/scitranslmed.3005708","volume":"5","author":"D Dalkara","year":"2013","unstructured":"Dalkara, D. et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci. Transl Med. 5, 189ra176 (2013).","journal-title":"Sci. Transl Med."},{"key":"205_CR78","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/gt.2015.74","volume":"22","author":"J Santiago-Ortiz","year":"2015","unstructured":"Santiago-Ortiz, J. et al. AAV ancestral reconstruction library enables selection of broadly infectious viral variants. Gene Ther. 22, 934\u2013946 (2015).","journal-title":"Gene Ther."},{"key":"205_CR79","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.celrep.2015.07.019","volume":"12","author":"E Zinn","year":"2015","unstructured":"Zinn, E. et al. In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector. Cell Rep. 12, 1056\u20131068 (2015).","journal-title":"Cell Rep."},{"key":"205_CR80","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nbt.3781","volume":"35","author":"LD Landegger","year":"2017","unstructured":"Landegger, L. D. et al. A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear. Nat. Biotechnol. 35, 280\u2013284 (2017).","journal-title":"Nat. Biotechnol."},{"key":"205_CR81","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nbt.3801","volume":"35","author":"B Pan","year":"2017","unstructured":"Pan, B. et al. Gene therapy restores auditory and vestibular function in a mouse model of Usher syndrome type 1c. Nat. Biotechnol. 35, 264\u2013272 (2017).","journal-title":"Nat. Biotechnol."},{"key":"205_CR82","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1128\/JVI.78.9.4421-4432.2004","volume":"78","author":"JE Rabinowitz","year":"2004","unstructured":"Rabinowitz, J. E. et al. Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J. Virol. 78, 4421\u20134432 (2004).","journal-title":"J. Virol."},{"key":"205_CR83","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jconrel.2017.08.005","volume":"262","author":"Z Chai","year":"2017","unstructured":"Chai, Z. et al. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion. J. Control Rel. 262, 348\u2013356 (2017).","journal-title":"J. Control Rel."},{"key":"205_CR84","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/mt.2010.170","volume":"18","author":"PE Monahan","year":"2010","unstructured":"Monahan, P. E. et al. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol. Ther. 18, 1907\u20131916 (2010).","journal-title":"Mol. Ther."},{"key":"205_CR85","doi-asserted-by":"publisher","first-page":"13035","DOI":"10.1128\/JVI.01826-13","volume":"87","author":"AM Mitchell","year":"2013","unstructured":"Mitchell, A. M. & Samulski, R. J. Mechanistic insights into the enhancement of adeno-associated virus transduction by proteasome inhibitors. J. Virol. 87, 13035\u201313041 (2013).","journal-title":"J. Virol."},{"key":"205_CR86","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.1128\/JVI.03443-12","volume":"87","author":"AM Mitchell","year":"2013","unstructured":"Mitchell, A. M., Li, C. & Samulski, R. J. Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction in vitro and in vivo. J. Virol. 87, 4571\u20134583 (2013).","journal-title":"J. Virol."},{"key":"205_CR87","doi-asserted-by":"publisher","first-page":"7019","DOI":"10.1128\/JVI.02953-15","volume":"90","author":"SC Nicolson","year":"2016","unstructured":"Nicolson, S. C., Li, C., Hirsch, M. L., Setola, V. & Samulski, R. J. Identification and validation of small molecules that enhance recombinant adeno-associated virus transduction following high-throughput screens. J. Virol. 90, 7019\u20137031 (2016).","journal-title":"J. Virol."},{"key":"205_CR88","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1074\/jbc.M115.687657","volume":"291","author":"GE Berry","year":"2016","unstructured":"Berry, G. E. & Asokan, A. Chemical modulation of endocytic sorting augments adeno-associated viral transduction. J. Biol. Chem. 291, 939\u2013947 (2016).","journal-title":"J. Biol. Chem."},{"key":"205_CR89","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1089\/hum.2017.220","volume":"29","author":"A Maddalena","year":"2018","unstructured":"Maddalena, A. et al. High-throughput screening identifies kinase inhibitors that increase dual adeno-associated viral vector transduction in vitro and in mouse retina. Hum. Gene Ther. 29, 886\u2013901 (2018).","journal-title":"Hum. Gene Ther."},{"key":"205_CR90","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.omtm.2019.05.012","volume":"14","author":"LC Chandler","year":"2019","unstructured":"Chandler, L. C. et al. Enhancement of adeno-associated virus-mediated gene therapy using hydroxychloroquine in murine and human tissues. Mol. Ther. Methods Clin. Dev. 14, 77\u201389 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"205_CR91","doi-asserted-by":"publisher","first-page":"6620","DOI":"10.1128\/JVI.00297-12","volume":"86","author":"J Denard","year":"2012","unstructured":"Denard, J. et al. Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. J. Virol. 86, 6620\u20136631 (2012).","journal-title":"J. Virol."},{"key":"205_CR92","doi-asserted-by":"publisher","first-page":"10784","DOI":"10.1128\/JVI.01813-13","volume":"87","author":"J Denard","year":"2013","unstructured":"Denard, J. et al. C-reactive protein (CRP) is essential for efficient systemic transduction of recombinant adeno-associated virus vector 1 (rAAV-1) and rAAV-6 in mice. J. Virol. 87, 10784\u201310791 (2013).","journal-title":"J. Virol."},{"key":"205_CR93","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/gt.2016.75","volume":"24","author":"M Wang","year":"2017","unstructured":"Wang, M. et al. Direct interaction of human serum proteins with AAV virions to enhance AAV transduction: immediate impact on clinical applications. Gene Ther. 24, 49\u201359 (2017).","journal-title":"Gene Ther."},{"key":"205_CR94","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.virol.2018.02.007","volume":"518","author":"X Pei","year":"2018","unstructured":"Pei, X. et al. AAV8 virions hijack serum proteins to increase hepatocyte binding for transduction enhancement. Virology 518, 95\u2013102 (2018).","journal-title":"Virology"},{"key":"205_CR95","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jconrel.2018.08.018","volume":"286","author":"Z Chai","year":"2018","unstructured":"Chai, Z. et al. Cryoprecipitate augments the global transduction of the adeno-associated virus serotype 9 after a systemic administration. J. Control Rel. 286, 415\u2013424 (2018).","journal-title":"J. Control Rel."},{"key":"205_CR96","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.omtm.2018.08.001","volume":"10","author":"J Denard","year":"2018","unstructured":"Denard, J. et al. AAV-8 and AAV-9 vectors cooperate with serum proteins differently than AAV-1 and AAV-6. Mol. Ther. Methods Clin. Dev. 10, 291\u2013302 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"205_CR97","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.omtm.2018.02.003","volume":"9","author":"Z Fitzpatrick","year":"2018","unstructured":"Fitzpatrick, Z. et al. Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV vector transduction. Mol. Ther. Methods Clin. Dev. 9, 119\u2013129 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"205_CR98","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/mt.2011.157","volume":"19","author":"AK Bevan","year":"2011","unstructured":"Bevan, A. K. et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol. Ther. 19, 1971\u20131980 (2011).","journal-title":"Mol. Ther."},{"key":"205_CR99","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/mtm.2013.12","volume":"1","author":"Y Liu","year":"2014","unstructured":"Liu, Y. et al. Enhancing gene delivery of adeno-associated viruses by cell-permeable peptides. Mol. Ther. Methods Clin. Dev. 1, 12 (2014).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"205_CR100","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.biomaterials.2018.05.041","volume":"176","author":"X Zhang","year":"2018","unstructured":"Zhang, X., He, T., Chai, Z., Samulski, R. J. & Li, C. Blood\u2013brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration. Biomaterials 176, 71\u201383 (2018).","journal-title":"Biomaterials"},{"key":"205_CR101","doi-asserted-by":"publisher","first-page":"10770","DOI":"10.1073\/pnas.0902269106","volume":"106","author":"C Li","year":"2009","unstructured":"Li, C. et al. Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc. Natl Acad. Sci. USA 106, 10770\u201310774 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"205_CR102","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.omtm.2018.07.011","volume":"10","author":"J Sun","year":"2018","unstructured":"Sun, J. et al. An observational study from long-term AAV re-administration in two hemophilia dogs. Mol. Ther. Methods Clin. Dev. 10, 257\u2013267 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"205_CR103","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1089\/hum.2017.016","volume":"28","author":"J Sun","year":"2017","unstructured":"Sun, J., Hua, B., Chen, X., Samulski, R. J. & Li, C. Gene delivery of activated factor VII using alternative adeno-associated virus serotype improves hemostasis in hemophiliac mice with FVIII inhibitors and adeno-associated virus neutralizing antibodies. Hum. Gene Ther. 28, 654\u2013666 (2017).","journal-title":"Hum. Gene Ther."},{"key":"205_CR104","first-page":"493","volume":"11","author":"BK Sack","year":"2009","unstructured":"Sack, B. K. & Herzog, R. W. Evading the immune response upon in vivo gene therapy with viral vectors. Curr. Opin. Mol. Ther. 11, 493\u2013503 (2009).","journal-title":"Curr. Opin. Mol. Ther."},{"key":"205_CR105","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S1074-7613(00)80349-0","volume":"6","author":"K Ahn","year":"1997","unstructured":"Ahn, K. et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 6, 613\u2013621 (1997).","journal-title":"Immunity"},{"key":"205_CR106","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1002\/j.1460-2075.1996.tb00689.x","volume":"15","author":"K Ahn","year":"1996","unstructured":"Ahn, K. et al. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J. 15, 3247\u20133255 (1996).","journal-title":"EMBO J."},{"key":"205_CR107","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/hmg\/ddx427","volume":"27","author":"W Shao","year":"2018","unstructured":"Shao, W., Chen, X., Samulski, R. J., Hirsch, M. L. & Li, C. Inhibition of antigen presentation during AAV gene therapy using virus peptides. Hum. Mol. Genet. 27, 601\u2013613 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"205_CR108","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99052","volume":"4","author":"Y Xiao","year":"2019","unstructured":"Xiao, Y. et al. Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity. JCI Insight 4, e99052 (2019).","journal-title":"JCI Insight"},{"key":"205_CR109","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1089\/hum.2008.161","volume":"20","author":"M Cooper","year":"2009","unstructured":"Cooper, M. et al. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Hum. Gene Ther. 20, 767\u2013776 (2009).","journal-title":"Hum. Gene Ther."},{"key":"205_CR110","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.4049\/jimmunol.0803965","volume":"182","author":"LE Mays","year":"2009","unstructured":"Mays, L. E. et al. Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins. J. Immunol. 182, 6051\u20136060 (2009).","journal-title":"J. Immunol."},{"key":"205_CR111","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1172\/JCI37607","volume":"119","author":"J Zhu","year":"2009","unstructured":"Zhu, J., Huang, X. & Yang, Y. The TLR9\u2013MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J. Clin. Invest. 119, 2388\u20132398 (2009). This study shows that an innate immune response is triggered soon after AAV transduction.","journal-title":"J. Clin. Invest."},{"key":"205_CR112","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","volume":"117","author":"AT Martino","year":"2011","unstructured":"Martino, A. T. et al. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 117, 6459\u20136468 (2011).","journal-title":"Blood"},{"key":"205_CR113","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1172\/JCI68205","volume":"123","author":"SM Faust","year":"2013","unstructured":"Faust, S. M. et al. CpG-depleted adeno-associated virus vectors evade immune detection. J. Clin. Invest. 123, 2994\u20133001 (2013).","journal-title":"J. Clin. Invest."},{"key":"205_CR114","first-page":"457","volume":"26","author":"YK Chan","year":"2018","unstructured":"Chan, Y. K. et al. Engineering AAV vectors to evade innate immune and inflammatory responses. Mol. Ther. 26, 457\u2013458 (2018).","journal-title":"Mol. Ther."},{"key":"205_CR115","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1016\/j.ymthe.2017.08.018","volume":"25","author":"FF Reichel","year":"2017","unstructured":"Reichel, F. F. et al. AAV8 can induce innate and adaptive immune response in the primate eye. Mol. Ther. 25, 2648\u20132660 (2017).","journal-title":"Mol. Ther."},{"key":"205_CR116","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/hgtb.2012.243","volume":"24","author":"V Louis Jeune","year":"2013","unstructured":"Louis Jeune, V., Joergensen, J. A., Hajjar, R. J. & Weber, T. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum. Gene Ther. Methods 24, 59\u201367 (2013).","journal-title":"Hum. Gene Ther. Methods"},{"key":"205_CR117","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1089\/hum.2017.150","volume":"28","author":"C Vandamme","year":"2017","unstructured":"Vandamme, C., Adjali, O. & Mingozzi, F. Unraveling the complex story of immune responses to AAV vectors trial after trial. Hum. Gene Ther. 28, 1061\u20131074 (2017).","journal-title":"Hum. Gene Ther."},{"key":"205_CR118","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.virol.2012.05.004","volume":"431","author":"DM McCraw","year":"2012","unstructured":"McCraw, D. M., O\u2019Donnell, J. K., Taylor, K. A., Stagg, S. M. & Chapman, M. S. Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20. Virology 431, 40\u201349 (2012).","journal-title":"Virology"},{"key":"205_CR119","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1128\/JVI.02710-14","volume":"89","author":"YS Tseng","year":"2015","unstructured":"Tseng, Y. S. et al. Adeno-associated virus serotype 1 (AAV1)\u2013 and AAV5\u2013antibody complex structures reveal evolutionary commonalities in parvovirus antigenic reactivity. J. Virol. 89, 1794\u20131808 (2015).","journal-title":"J. Virol."},{"key":"205_CR120","doi-asserted-by":"publisher","first-page":"7752","DOI":"10.1128\/JVI.00675-12","volume":"86","author":"C Li","year":"2012","unstructured":"Li, C. et al. Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J. Virol. 86, 7752\u20137759 (2012).","journal-title":"J. Virol."},{"key":"205_CR121","doi-asserted-by":"publisher","unstructured":"Jose, A. et al. High resolution structural characterization of a new AAV5 antibody epitope toward engineering antibody resistant recombinant gene delivery vectors. J. Virol. https:\/\/doi.org\/10.1128\/JVI.01394-18 (2018).","DOI":"10.1128\/JVI.01394-18"},{"key":"205_CR122","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006929","volume":"14","author":"JK Smith","year":"2018","unstructured":"Smith, J. K. & Agbandje-McKenna, M. Creating an arsenal of adeno-associated virus (AAV) gene delivery stealth vehicles. PLOS Pathog. 14, e1006929 (2018).","journal-title":"PLOS Pathog."},{"key":"205_CR123","doi-asserted-by":"publisher","first-page":"E4812","DOI":"10.1073\/pnas.1704766114","volume":"114","author":"LV Tse","year":"2017","unstructured":"Tse, L. V. et al. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proc. Natl Acad. Sci. USA 114, E4812\u2013E4821 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"205_CR124","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/jgm.967","volume":"8","author":"DA Waterkamp","year":"2006","unstructured":"Waterkamp, D. A., Muller, O. J., Ying, Y., Trepel, M. & Kleinschmidt, J. A. Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307\u20131319 (2006).","journal-title":"J. Gene Med."},{"key":"205_CR125","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1128\/JVI.00254-08","volume":"82","author":"D Grimm","year":"2008","unstructured":"Grimm, D. et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82, 5887\u20135911 (2008).","journal-title":"J. Virol."},{"key":"205_CR126","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mt.2015.134","volume":"24","author":"C Li","year":"2016","unstructured":"Li, C. et al. Development of patient-specific AAV vectors after neutralizing antibody selection for enhanced muscle gene transfer. Mol. Ther. 24, 53\u201365 (2016).","journal-title":"Mol. Ther."},{"key":"205_CR127","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ymthe.2017.09.021","volume":"26","author":"NK Paulk","year":"2018","unstructured":"Paulk, N. K. et al. Bioengineered AAV capsids with combined high human liver transduction in vivo and unique humoral seroreactivity. Mol. Ther. 26, 289\u2013303 (2018).","journal-title":"Mol. Ther."},{"key":"205_CR128","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1172\/JCI66611","volume":"123","author":"C Li","year":"2013","unstructured":"Li, C. et al. Adeno-associated virus capsid antigen presentation is dependent on endosomal escape. J. Clin. Invest. 123, 1390\u20131401 (2013).","journal-title":"J. Clin. Invest."},{"key":"205_CR129","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3389\/fimmu.2018.00844","volume":"9","author":"X Pei","year":"2018","unstructured":"Pei, X. et al. Efficient capsid antigen presentation from adeno-associated virus empty virions. Vivo. Front. Immunol. 9, 844 (2018).","journal-title":"Vivo. Front. Immunol."},{"key":"205_CR130","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1089\/hgtb.2012.195","volume":"24","author":"D Sen","year":"2013","unstructured":"Sen, D. et al. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo. Hum. Gene Ther. Methods 24, 104\u2013116 (2013).","journal-title":"Hum. Gene Ther. Methods"},{"key":"205_CR131","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood-2012-10-460733","volume":"121","author":"AT Martino","year":"2013","unstructured":"Martino, A. T. et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224\u20132233 (2013).","journal-title":"Blood"},{"key":"205_CR132","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/btm2.10090","volume":"3","author":"WF Kaemmerer","year":"2018","unstructured":"Kaemmerer, W. F. How will the field of gene therapy survive its success? Bioeng. Transl Med. 3, 166\u2013177 (2018).","journal-title":"Bioeng. Transl Med."},{"key":"205_CR133","doi-asserted-by":"publisher","first-page":"R2","DOI":"10.1093\/hmg\/ddr141","volume":"20","author":"RM Kotin","year":"2011","unstructured":"Kotin, R. M. Large-scale recombinant adeno-associated virus production. Hum. Mol. Genet. 20, R2\u2013R6 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"205_CR134","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/mt.2015.187","volume":"24","author":"JC Grieger","year":"2016","unstructured":"Grieger, J. C., Soltys, S. M. & Samulski, R. J. Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. Mol. Ther. 24, 287\u2013297 (2016).","journal-title":"Mol. Ther."},{"key":"205_CR135","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.omtm.2018.01.002","volume":"8","author":"M Penaud-Budloo","year":"2018","unstructured":"Penaud-Budloo, M., Francois, A., Clement, N. & Ayuso, E. Pharmacology of recombinant adeno-associated virus production. Mol. Ther. Methods Clin. Dev. 8, 166\u2013180 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"205_CR136","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1089\/hum.2017.042","volume":"28","author":"RM Kotin","year":"2017","unstructured":"Kotin, R. M. & Snyder, R. O. Manufacturing clinical grade recombinant adeno-associated virus using invertebrate cell lines. Hum. Gene Ther. 28, 350\u2013360 (2017).","journal-title":"Hum. Gene Ther."},{"key":"205_CR137","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1089\/hum.2013.184","volume":"25","author":"M Mietzsch","year":"2014","unstructured":"Mietzsch, M. et al. OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1\u201312 vectors for gene therapy. Hum. Gene Ther. 25, 212\u2013222 (2014).","journal-title":"Hum. Gene Ther."},{"key":"205_CR138","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1016\/j.ymthe.2017.08.003","volume":"25","author":"O Kondratov","year":"2017","unstructured":"Kondratov, O. et al. Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells. Mol. Ther. 25, 2661\u20132675 (2017).","journal-title":"Mol. Ther."},{"key":"205_CR139","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41434-018-0034-7","volume":"25","author":"B Bosma","year":"2018","unstructured":"Bosma, B. et al. Optimization of viral protein ratios for production of rAAV serotype 5 in the baculovirus system. Gene Ther. 25, 415\u2013424 (2018).","journal-title":"Gene Ther."},{"key":"205_CR140","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.omtm.2017.11.002","volume":"7","author":"Q Wang","year":"2017","unstructured":"Wang, Q. et al. A robust system for production of superabundant VP1 recombinant AAV vectors. Mol. Ther. Methods Clin. Dev. 7, 146\u2013156 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"205_CR141","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.omtm.2018.09.005","volume":"11","author":"Z Wang","year":"2018","unstructured":"Wang, Z., Cheng, F., Engelhardt, J. F., Yan, Z. & Qiu, J. Development of a novel recombinant adeno-associated virus production system using human bocavirus 1 helper genes. Mol. Ther. Methods Clin. Dev. 11, 40\u201351 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"205_CR142","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00710-17","author":"Z Wang","year":"2017","unstructured":"Wang, Z. et al. Human bocavirus 1 is a novel helper for adeno-associated virus replication. J. Virol. https:\/\/doi.org\/10.1128\/JVI.00710-17 (2017).","journal-title":"J. Virol."},{"key":"205_CR143","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/sj.gt.3300938","volume":"6","author":"S Zolotukhin","year":"1999","unstructured":"Zolotukhin, S. et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6, 973\u2013985 (1999).","journal-title":"Gene Ther."},{"key":"205_CR144","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1006\/mthe.2001.0462","volume":"4","author":"A Auricchio","year":"2001","unstructured":"Auricchio, A., O\u2019Connor, E., Hildinger, M. & Wilson, J. M. A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors. Mol. Ther. 4, 372\u2013374 (2001).","journal-title":"Mol. Ther."},{"key":"205_CR145","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1089\/hum.1998.9.18-2745","volume":"9","author":"D Grimm","year":"1998","unstructured":"Grimm, D., Kern, A., Rittner, K. & Kleinschmidt, J. A. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum. Gene Ther. 9, 2745\u20132760 (1998).","journal-title":"Hum. Gene Ther."},{"key":"205_CR146","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/mt.2009.128","volume":"17","author":"RH Smith","year":"2009","unstructured":"Smith, R. H., Levy, J. R. & Kotin, R. M. A simplified baculovirus\u2013AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol. Ther. 17, 1888\u20131896 (2009).","journal-title":"Mol. Ther."},{"key":"205_CR147","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ymthe.2006.02.014","volume":"14","author":"GS Arnold","year":"2006","unstructured":"Arnold, G. S., Sasser, A. K., Stachler, M. D. & Bartlett, J. S. Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97\u2013106 (2006).","journal-title":"Mol. Ther."},{"key":"205_CR148","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1089\/hum.2006.139","volume":"18","author":"JT Koerber","year":"2007","unstructured":"Koerber, J. T., Jang, J. H., Yu, J. H., Kane, R. S. & Schaffer, D. V. Engineering adeno-associated virus for one-step purification via immobilized metal affinity chromatography. Hum. Gene Ther. 18, 367\u2013378 (2007).","journal-title":"Hum. Gene Ther."},{"key":"205_CR149","doi-asserted-by":"publisher","first-page":"15040","DOI":"10.1038\/mtm.2015.40","volume":"2","author":"Q Wang","year":"2015","unstructured":"Wang, Q. et al. Identification of an adeno-associated virus binding epitope for AVB Sepharose affinity resin. Mol. Ther. Methods Clin. Dev. 2, 15040 (2015).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"205_CR150","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jviromet.2006.11.019","volume":"140","author":"G Qu","year":"2007","unstructured":"Qu, G. et al. Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. J. Virol. Methods 140, 183\u2013192 (2007).","journal-title":"J. Virol. Methods"},{"key":"205_CR151","doi-asserted-by":"publisher","first-page":"194ra192","DOI":"10.1126\/scitranslmed.3005795","volume":"5","author":"F Mingozzi","year":"2013","unstructured":"Mingozzi, F. et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci. Transl Med. 5, 194ra192 (2013).","journal-title":"Sci. Transl Med."},{"key":"205_CR152","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.omtm.2017.12.004","volume":"9","author":"SA Nass","year":"2018","unstructured":"Nass, S. A. et al. Universal method for the purification of recombinant AAV vectors of differing serotypes. Mol. Ther. Methods Clin. Dev. 9, 33\u201346 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"205_CR153","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.neulet.2017.11.049","volume":"665","author":"Y Matsuzaki","year":"2018","unstructured":"Matsuzaki, Y. et al. Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain. Neurosci. Lett. 665, 182\u2013188 (2018).","journal-title":"Neurosci. Lett."},{"key":"205_CR154","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","volume":"26","author":"J Hordeaux","year":"2018","unstructured":"Hordeaux, J. et al. The neurotropic properties of AAV-PHP.B are limited to C57BL\/6J Mice. Mol. Ther. 26, 664\u2013668 (2018).","journal-title":"Mol. Ther."},{"key":"205_CR155","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1200-1","volume":"15","author":"DM Markusic","year":"2017","unstructured":"Markusic, D. M. et al. Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models. J. Transl Med. 15, 94 (2017).","journal-title":"J. Transl Med."},{"key":"205_CR156","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/mt.2011.119","volume":"19","author":"JB Nietupski","year":"2011","unstructured":"Nietupski, J. B. et al. Systemic administration of AAV8\u2013\u03b1-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression. Mol. Ther. 19, 1999\u20132011 (2011).","journal-title":"Mol. Ther."},{"key":"205_CR157","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature12875","volume":"506","author":"L Lisowski","year":"2014","unstructured":"Lisowski, L. et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 506, 382\u2013386 (2014). This study uses chimeric humanized mice to select novel AAV mutants.","journal-title":"Nature"},{"key":"205_CR158","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/mt.2015.174","volume":"23","author":"S Li","year":"2015","unstructured":"Li, S. et al. Efficient and targeted transduction of nonhuman primate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867\u20131876 (2015).","journal-title":"Mol. Ther."},{"key":"205_CR159","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/mt.2015.179","volume":"23","author":"L Wang","year":"2015","unstructured":"Wang, L. et al. Comparative study of liver gene transfer with AAV vectors based on natural and engineered AAV capsids. Mol. Ther. 23, 1877\u20131887 (2015).","journal-title":"Mol. Ther."},{"key":"205_CR160","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/mt.2016.61","volume":"24","author":"K Vercauteren","year":"2016","unstructured":"Vercauteren, K. et al. Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042\u20131049 (2016).","journal-title":"Mol. Ther."},{"key":"205_CR161","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41434-019-0104-5","volume":"26","author":"W Shao","year":"2019","unstructured":"Shao, W. et al. Superior human hepatocyte transduction with adeno-associated virus vector serotype 7. Gene Ther. 26, 504\u2013514 (2019).","journal-title":"Gene Ther."},{"key":"205_CR162","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1038\/mt.2015.206","volume":"23","author":"MA Kay","year":"2015","unstructured":"Kay, M. A. Selecting the best AAV capsid for human studies. Mol. Ther. 23, 1800\u20131801 (2015).","journal-title":"Mol. Ther."},{"key":"205_CR163","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1093\/hmg\/ddu028","volume":"23","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y. et al. Human skeletal muscle xenograft as a new preclinical model for muscle disorders. Hum. Mol. Genet. 23, 3180\u20133188 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"205_CR164","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1146\/annurev-pathol-052016-100332","volume":"12","author":"NC Walsh","year":"2017","unstructured":"Walsh, N. C. et al. Humanized mouse models of clinical disease. Annu. Rev. Pathol. 12, 187\u2013215 (2017).","journal-title":"Annu. Rev. Pathol."},{"key":"205_CR165","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41576-018-0051-9","volume":"19","author":"G Rossi","year":"2018","unstructured":"Rossi, G., Manfrin, A. & Lutolf, M. P. Progress and potential in organoid research. Nat. Rev. Genet. 19, 671\u2013687 (2018).","journal-title":"Nat. Rev. Genet."},{"key":"205_CR166","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nbt.2643","volume":"31","author":"A Gonzalez-Cordero","year":"2013","unstructured":"Gonzalez-Cordero, A. et al. Photoreceptor precursors derived from three-dimensional embryonic stem cell cultures integrate and mature within adult degenerate retina. Nat. Biotechnol. 31, 741\u2013747 (2013).","journal-title":"Nat. Biotechnol."},{"key":"205_CR167","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1167\/iovs.16-19087","volume":"57","author":"T Santos-Ferreira","year":"2016","unstructured":"Santos-Ferreira, T. et al. Stem cell-derived photoreceptor transplants differentially integrate into mouse models of cone\u2013rod dystrophy. Invest. Ophthalmol. Vis. Sci. 57, 3509\u20133520 (2016).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"205_CR168","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1128\/JVI.01990-07","volume":"82","author":"AK Zaiss","year":"2008","unstructured":"Zaiss, A. K. et al. Complement is an essential component of the immune response to adeno-associated virus vectors. J. Virol. 82, 2727\u20132740 (2008).","journal-title":"J. Virol."},{"key":"205_CR169","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/14712598.2018.1389886","volume":"18","author":"NA Moore","year":"2018","unstructured":"Moore, N. A., Morral, N., Ciulla, T. A. & Bracha, P. Gene therapy for inherited retinal and optic nerve degenerations. Expert. Opin. Biol. Ther. 18, 37\u201349 (2018).","journal-title":"Expert. Opin. Biol. Ther."},{"key":"205_CR170","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","volume":"372","author":"JW Bainbridge","year":"2015","unstructured":"Bainbridge, J. W. et al. Long-term effect of gene therapy on Leber\u2019s congenital amaurosis. N. Engl. J. Med. 372, 1887\u20131897 (2015). This paper presents findings that led to the first AAV-based drug, Luxturna, being approved by the FDA.","journal-title":"N. Engl. J. Med."},{"key":"205_CR171","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1412965","volume":"372","author":"SG Jacobson","year":"2015","unstructured":"Jacobson, S. G. et al. Improvement and decline in vision with gene therapy in childhood blindness. N. Engl. J. Med. 372, 1920\u20131926 (2015).","journal-title":"N. Engl. J. Med."},{"key":"205_CR172","doi-asserted-by":"publisher","first-page":"E517","DOI":"10.1073\/pnas.1218933110","volume":"110","author":"AV Cideciyan","year":"2013","unstructured":"Cideciyan, A. V. et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc. Natl Acad. Sci. USA 110, E517\u2013E525 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"205_CR173","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1182\/blood-2018-07-820720","volume":"133","author":"GQ Perrin","year":"2019","unstructured":"Perrin, G. Q., Herzog, R. W. & Markusic, D. M. Update on clinical gene therapy for hemophilia. Blood 133, 407\u2013414 (2019).","journal-title":"Blood"},{"key":"205_CR174","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","volume":"131","author":"W Miesbach","year":"2018","unstructured":"Miesbach, W. et al. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood 131, 1022\u20131031 (2018).","journal-title":"Blood"},{"key":"205_CR175","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrd.2018.110","volume":"17","author":"BE Deverman","year":"2018","unstructured":"Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M. & Sah, D. W. Y. Gene therapy for neurological disorders: progress and prospects. Nat. Rev. Drug. Discov. 17, 641\u2013659 (2018).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"205_CR176","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S2352-4642(17)30125-6","volume":"1","author":"YH Chien","year":"2017","unstructured":"Chien, Y. H. et al. Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1\/2 trial. Lancet. Child. Adolesc. Health 1, 265\u2013273 (2017).","journal-title":"Lancet. Child. Adolesc. Health"},{"key":"205_CR177","doi-asserted-by":"publisher","first-page":"165ra163","DOI":"10.1126\/scitranslmed.3003454","volume":"4","author":"P Leone","year":"2012","unstructured":"Leone, P. et al. Long-term follow-up after gene therapy for canavan disease. Sci. Transl Med. 4, 165ra163 (2012).","journal-title":"Sci. Transl Med."},{"key":"205_CR178","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","volume":"26","author":"D Duan","year":"2018","unstructured":"Duan, D. & Systemic, A. A. V. Micro-dystrophin gene therapy for duchenne muscular dystrophy. Mol. Ther. 26, 2337\u20132356 (2018).","journal-title":"Mol. Ther."},{"key":"205_CR179","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14712598.2018.1479739","volume":"18","author":"S Aguti","year":"2018","unstructured":"Aguti, S., Malerba, A. & Zhou, H. The progress of AAV-mediated gene therapy in neuromuscular disorders. Expert Opin. Biol. Ther. 18, 681\u2013693 (2018).","journal-title":"Expert Opin. Biol. Ther."},{"key":"205_CR180","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCRESAHA.118.311587","volume":"123","author":"K Ishikawa","year":"2018","unstructured":"Ishikawa, K., Weber, T. & Hajjar, R. J. Human cardiac gene therapy. Circ. Res. 123, 601\u2013613 (2018).","journal-title":"Circ. Res."},{"key":"205_CR181","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","volume":"387","author":"B Greenberg","year":"2016","unstructured":"Greenberg, B. et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet 387, 1178\u20131186 (2016).","journal-title":"Lancet"},{"key":"205_CR182","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.ymthe.2017.03.029","volume":"25","author":"C Mueller","year":"2017","unstructured":"Mueller, C. et al. 5 Year expression and neutrophil defect repair after gene therapy in \u03b1-1 antitrypsin deficiency. Mol. Ther. 25, 1387\u20131394 (2017).","journal-title":"Mol. Ther."},{"key":"205_CR183","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jhep.2016.05.012","volume":"65","author":"D D'Avola","year":"2016","unstructured":"D\u2019Avola, D. et al. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J. Hepatol. 65, 776\u2013783 (2016).","journal-title":"J. Hepatol."},{"key":"205_CR184","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","volume":"4","author":"CS Lee","year":"2017","unstructured":"Lee, C. S. et al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis. 4, 43\u201363 (2017).","journal-title":"Genes Dis."},{"key":"205_CR185","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1089\/hum.2017.218","volume":"29","author":"WW Zhang","year":"2018","unstructured":"Zhang, W. W. et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Hum. Gene Ther. 29, 160\u2013179 (2018).","journal-title":"Hum. Gene Ther."},{"key":"205_CR186","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.clim.2017.07.006","volume":"189","author":"PR Lowenstein","year":"2018","unstructured":"Lowenstein, P. R. & Castro, M. G. Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. Clin. Immunol. 189, 43\u201351 (2018).","journal-title":"Clin. Immunol."},{"key":"205_CR187","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.cell.2016.06.049","volume":"166","author":"J Hoggatt","year":"2016","unstructured":"Hoggatt, J. Gene therapy for \u201cBubble Boy\u201d disease. Cell 166, 263 (2016).","journal-title":"Cell"},{"key":"205_CR188","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nbt0817-691","volume":"35","author":"C Sheridan","year":"2017","unstructured":"Sheridan, C. First approval in sight for Novartis\u2019 CAR-T therapy after panel vote. Nat. Biotechnol. 35, 691\u2013693 (2017).","journal-title":"Nat. Biotechnol."},{"key":"205_CR189","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/blood-2018-04-839217","volume":"132","author":"VA Chow","year":"2018","unstructured":"Chow, V. A., Shadman, M. & Gopal, A. K. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed\/refractory diffuse large B-cell lymphoma. Blood 132, 777\u2013781 (2018).","journal-title":"Blood"}],"container-title":["Nature Reviews Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41576-019-0205-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41576-019-0205-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41576-019-0205-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T13:51:29Z","timestamp":1684849889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41576-019-0205-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":189,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["205"],"URL":"https:\/\/doi.org\/10.1038\/s41576-019-0205-4","relation":{},"ISSN":["1471-0056","1471-0064"],"issn-type":[{"value":"1471-0056","type":"print"},{"value":"1471-0064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,10]]},"assertion":[{"value":"3 December 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.J.S. is the founder and a shareholder at Asklepios BioPharmaceutical and Bamboo Therapeutics, Inc. He holds patents that have been licensed by University of North Carolina to Asklepios Biopharmaceutical, for which he receives royalties. He has consulted for Baxter Healthcare and has received payment for speaking. C.L. is a cofounder of Bedrock Therapeutics, Inc. He holds patents licensed by University of North Carolina and has received royalties from Bedrock Therapeutics and Asklepios Biopharmaceutical.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}